A Study of the Effect of Tazemetostat (study drug) in Patients with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma To assess the overall response rate (ORR) in subjects with rhabdoid tumors (Cohort 1) and other INI1-negative tumors (Cohort 3) following oral administration of tazemetostat 800 mg twice daily (BID) ...

• Country None
• organs None
• Specialty None

Rollover Study for Tazemetostat Etude d'extension du Tazemetostat 1. Number of subjects with adverse events related to study drug, as a measure of safety and tolerability of tazemetostat 2. Number of subjects with adverse events, as a measure of safety and tolerabi...

• Country None
• organs None
• Specialty None

A Study on the Effect of Tazemetostat (study drug) in Patients with Advanced Solid Tumors or with B Cell Lymphomas Phase 1 To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of tazemetostat as a single agent administered orally twice daily (BID), continuously in 28-day cycl...

• Country None
• organs None
• Specialty None

A Study on the Effect of Tazemetostat (study drug) in Pediatric Subjects with relapsed or refractory Tumors or Synovial Sarcoma Dose Escalation: To determine the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D) of tazemetostat when administered as an oral suspension twice daily (BID) in pediatric subjects w...

• Country None
• organs None
• Specialty None

A Study of the Effect of Tazemetostat (study drug) in Patients with Relapsed or Refractory Mesothelioma Etude des effets du Tazemetostat (produit à l'étude) chez des patients tteints d'un mésothéliome malin en rechute ou réfractaire Part 1 (Pharmacokinetics) To assess the pharmacokinetic (PK) and safety profile of single and repeated doses of 800 mg tazemetostat administered as 400 mg tablets in subjects with relapsed or refracto...

• Country None
• organs None
• Specialty None